Azitra, Inc. Announces Reverse Stock Split
2024年6月28日 - 5:05AM
ビジネスワイヤ(英語)
Common Stock Will Begin Trading on a
Split-Adjusted Basis on July 1, 2024
Azitra, Inc. (NYSE American: AZTR), a clinical-stage
biopharmaceutical company focused on developing innovative
therapies for precision dermatology, today announced that it
intends to effect a reverse stock split of its common stock at a
ratio of 1 post-split share for every 30 pre-split shares. The
reverse stock split will become effective at 12:01 A.M. Eastern
Time, on July 1, 2024. The Company's common stock will continue to
be traded on the NYSE American under the symbol “AZTR” and will
begin trading on a split-adjusted basis when the market opens on
July 1, 2024. The new CUSIP number for the Company’s common stock
following the reverse stock split will be 05479L 203.
At a special meeting of stockholders held on June 27, 2024, the
Company's stockholders granted the Company's Board of Directors the
discretion to effect a reverse stock split of the Company's common
stock through an amendment to its Second Amended and Restated
Certificate of Incorporation, as amended, at a ratio of not less
than 1-for-2 and not more than 1-for-30, with such ratio to be
determined by the Company's Board of Directors. Following the
stockholders meeting, the Board of Directors of Azitra approved the
final split ratio of 1-for-30 and the effective date of July 1,
2024.
At the effective time of the reverse stock split, every 30
shares of the Company's issued common stock will be converted
automatically into one issued share of common stock without any
change in the par value per share. Stockholders holding shares
through a brokerage account will have their shares automatically
adjusted to reflect the 1-for-30 reverse stock split. It is not
necessary for stockholders holding shares of the Company's common
stock in certificated form to exchange their existing stock
certificates for new stock certificates of the Company in
connection with the reverse stock split, although stockholders may
do so if they wish.
The reverse stock split will affect all stockholders uniformly
and will not alter any stockholder's percentage interest in the
Company's equity, except to the extent that the reverse stock split
would result in a stockholder owning a fractional share. No
fractional shares of common stock will be issued in connection with
the reverse split. Stockholders of record who otherwise would be
entitled to receive fractional shares, will be entitled to receive
cash (without interest) in lieu of fractional shares, equal to such
fraction multiplied by the average of the closing sales prices of
the common stock on the NYSE American during regular trading hours
for the five consecutive trading days immediately preceding the
effective date of the reverse split (with such average closing
sales prices being adjusted to give effect to the reverse
split).
The reverse stock split will reduce the number of issued shares
of the Company's common stock from 28,804,643 shares to
approximately 960,155 shares. Proportional adjustments will be made
to the number of shares of the Company's common stock issuable upon
exercise or conversion of the Company’s equity awards and warrants,
as well as the applicable exercise price. Stockholders whose shares
are held in brokerage accounts should direct any questions
concerning the reverse stock split to their broker. All
stockholders of record may direct questions to the Company's
transfer agent, VStock Transfer Company, at
action@vstocktransfer.com.
Additional information about the reverse stock split can be
found in the Company’s definitive proxy statement filed with the
Securities and Exchange Commission (the “SEC”) on June 3, 2024,
which is available free of charge at the SEC’s website,
www.sec.gov, and on the Company’s website at
https://ir.azitrainc.com/.
About Azitra, Inc.
Azitra, Inc. is an early-stage clinical biopharmaceutical
company focused on developing innovative therapies for precision
dermatology using engineered proteins and topical live
biotherapeutic products. The Company has built a proprietary
platform that includes a microbial library comprised of
approximately 1,500 unique bacterial strains that can be screened
for unique therapeutic characteristics. The platform is augmented
by artificial intelligence and machine learning technology that
analyzes, predicts, and helps screen the Company's library of
strains for drug like molecules. The Company's initial focus is on
the development of genetically engineered strains of Staphylococcus
epidermidis, or S. epidermidis, which the Company considers to be
an optimal therapeutic candidate species for engineering of
dermatologic therapies. For more information, please visit
https://azitrainc.com/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240627507455/en/
Investor Relations Contact: Norman Staskey Chief
Financial Officer staskey@azitrainc.com
Hayden IR James Carbonara (646) 755-7412 james@haydenir.com
Azitra (AMEX:AZTR)
過去 株価チャート
から 7 2024 まで 8 2024
Azitra (AMEX:AZTR)
過去 株価チャート
から 8 2023 まで 8 2024